Back to Journals » Cancer Management and Research » Volume 11

Expression of PD-L1 in cervical carcinoma and its impact on survival associated with T-cell infiltration and FoxP3 expression

Authors Grochot RM, Brollo J, Neto FR, Tregnago AC, Scholze C, Norris R, Silva S, Weschenfelder DC, Reiriz AB, Michelin L, Pasqualotto FF

Received 14 November 2018

Accepted for publication 26 March 2019

Published 17 May 2019 Volume 2019:11 Pages 4597—4605


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Lu-Zhe Sun

Rafael M Grochot,1,2 Janaína Brollo,2 Floriano Riva Neto,2,3 Aline C Tregnago,2,3 Cassiano Scholze,3 Rui Norris,3 Sargeele Silva,2 Débora C Weschenfelder,2 André B Reiriz,1,2 Lessandra Michelin,1 Fábio F Pasqualotto1

1Department of Health Sciences, School of Medicine, University of Caxias do Sul, Caxias do Sul, RS, Brazil; 2UNACON Cancer Center, Caxias do Sul General Hospital, Caxias do Sul, RS, Brazil; 3CPM Laboratory, Caxias do Sul, RS, Brazil

Background: The PD-1/PD-L1 signaling axis is currently the most elucidated mechanism for tumor evasion of T-cell-mediated immunity. Nevertheless, few data are available regarding its impact on cervical cancer and the relationship with lymphocytic infiltrates.
Methods: A retrospective assessment of all cases of cervical neoplasia treated in Caxias do Sul General Hospital, Brazil, between 2012 and 2016 was performed. Clinical and pathological data were collected from electronic records and analyzed. Original slides were independently reviewed by three pathologists to confirm diagnoses and to assess the immunohistochemical expression of PD-L1 and FoxP3 in tumor cells and lymphocytic infiltrates.
Results: PD-L1 staining was present in 32.2% of the 59 cervical samples. Median overall survival time of the PD-L1-negative group was 47.8 months, a time point not yet reached by the PD-L1-positive group (p=0.968). Median progression-free survival was 24.3 months for PD-L1-negative and 11.5 months for PD-L1-positive patients (p=0.263). PD-L1 staining was found in 27.1% of the lymphocytic infiltrates, and survival analysis revealed no difference between PD-L1-positive and PD-L1-negative samples. There was no impact on survival related to FoxP3 staining in neither tumor samples nor lymphocytic infiltrates.
Conclusion: Although the median progression-free survival times differed, the difference was not statistically significant. Our study corroborates the rationale that PD-L1 expression in cervical neoplasms has no impact on survival. PD-L1 expression in peritumoral lymphocytes revealed no impact on infiltration volume nor survival.

Keywords: uterine cervical neoplasms, tumor-infiltrating lymphocytes, cancer, tumor microenvironment, survival

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]